Drug intelligence / Profile preview

MC004

Development stage: Preclinical
Lead developer: Medicovestor
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MC004 is a naked monoclonal antibody targeting folate receptor alpha (FRα), currently in IND-enabling development by Medicovestor. It is being developed for the treatment of endometriosis and malignant mesothelioma. By binding to FRα, which is overexpressed in certain inflammatory and malignant tissues, MC004 aims to modulate or inhibit FRα-mediated pathways to treat these conditions.

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on MC004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC004.

Explore the full profile